Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon-Reference-Cited by-同舟云学术

Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon

Published:2006-02 Issue:2 Volume:17 Page:281-285
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Latagliata R.,Bongarzoni V.,Carmosino I.,Mengarelli A.,Breccia M.,Borza P.A.,D'Andrea M.,D'Elia G.M.,Mecarocci S.,Morano S.G.,Petti M.C.,Mandelli F.,Alimena G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/2/281/393034/mdj112.pdf

Reference18 articles.

1. De novo acute myeloid leukemia in patients over 55-years-old: a population-based study of incidence;Taylor;treatment and outcome. Leukemia,1995

2. Age at death and rectangularisation of the survival curve:trends in Switzerland, 1969–1994;Paccaud;J Epidemiol Community Health,1998

3. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

4. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients;Witz;Blood,1998

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-intensive acute myeloid leukemia therapies for older patients;Expert Review of Hematology;2023-03-02

2. Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making;Oncology and Therapy;2022-06-13

3. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia;Future Oncology;2021-08

4. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia;Expert Review of Hematology;2021-05-04

5. Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid;Cancers;2021-04-29